Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 15 of 15 publications.

Poonawalla I, Bowe A, Tindal M, Meah Y, Schwab P. SGLT2 inhibitors: comparative effectiveness of SGLT2 inhibitors vs GLP1 agonists. Presented at the 80th American Diabetes Association Scientific Sessions; June 12, 2020.

Schwab P, Poonawalla I, Bowe A, Tindal M, Meah Y. SGLT2 inhibitors: a comparison of cardiovascular, medical and cost outcomes. Presented at the 80th American Diabetes Association Scientific Sessions; June 12, 2020.

Critchlow C, Chinn C, Price MA. Blurring the division between clinical and observational studies. Presented at the 9th Annual SCOPE Summit Conference; February 13, 2018. Orlando, FL.

Price MA, Richardson D. Value of conducting feasibility studies in observational research. Presented at the 9th Annual SCOPE Summit Conference; February 13, 2018. Orlando, FL.

Sussman G, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst AC, Lacour J-P, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Reynolds M, Weller K, Balp M-M. Angioedema in patients with chronic spontaneous urticaria has an additional impact of quality of life but is reported more often by patients than physicians. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.

Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Davenport E, Bello T. Secukinumab patients achieve high overall treatment satisfaction and psoriasis-related and symptom improvement in a real world setting. Presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Marsland A, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Hunter S, Khalil S, Knulst AC, Lacour L-P, Lynde C, McBride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Sussman G, Tian H, Weller K, Maurer M. Chronic spontaneous/idiopathic urticaria patients with moderate activity have similar burden of disease as those with severe activity - results from the ASSURE-CSU study. Presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.

Price MA, Hamm L. Synergies in the operationalization of clinical and observational studies. Presented at the 8th Annual SCOPE Summit Conference; January 24, 2017. Miami, FL.

Silvia S, Hollis K, Wooddell MJ, Hogue S, White MV. The Epipen4schools® survey: prevalence and triggers of anaphylactic events in large US school districts. Presented at the 2015 ACAAI Conference; November 2015. San Antonio, TX.

DiCesare J, Garrison L, Oster G, Sacco P. Assessing the reimbursability of new products: a structured approach. Presented at the 2012 ISPOR EUR Workshop; November 2012. Berlin, Germany.

Zografos L. Considerations for implementing surveys evaluating effectiveness: sample recruitment, ethics, and privacy. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 5, 2012. Barcelona.

Hollis KA, Mordin MM, Bechtel P, McLeod LD. Prospective observational studies: avoiding design pitfalls using process maps, decision-tree methods, and electronic medical records. Presented at the International Society for Pharmacoeconomics and Outcomes Research 15th Annual; May 2010.

Borah B, Sacco P, Zarotsky V. Predictors of adherence among alzheimer's disease patients receiving oral therapy: results of a retrospective database analysis. Presented at the American Academy of Neurology; April 2010. Toronto, Canada.

Wertz DA, Pollack M, Bohn R, Rodgers K, Sacco P, Sullivan SD. Impact of asthma control on quality of life. Presented at the American Academy of Allergy, Asthma, and Immunology; May 2008. Washington, DC.

Hollis KA, Duffer A. The use of panels as an effective means of collecting patient-reported outcomes. Presented at the Drug Information Association's 9th Annual Symposium for Quality of Life Evaluation; March 2002.